Advertisement
Advertisement

NKTR

NKTR logo

Nektar Therapeutics

73.02
USD
Sponsored
+1.27
+1.77%
Sep 02, 09:55 UTC -4
Open

Nektar Therapeutics Profile

About

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Pfizer, Roche, Amgen, Bristol-Myers and Eli Lilly among others. The company's most lucrative deal is with Bristol-Myers, which provided the company with significant cash resources to support progress of its pipeline and share development costs for its lead candidate, bempegaldesleukin. Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology platforms. Amgen's neutropenia drug, Neulasta is one of the drugs developed using Nektar's PEGylation platform.

Info & Links

CEO

Howard W. Robin

Headquarters

455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO, CA 94158, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.nektar.com

Auditor

Ernst & Young LLP

Share holders

130

Employees

63

Nektar Therapeutics Statistics

Valuation Measures

Market Capitalization2

2.49B

Enterprise Value

2.45B

Enterprise Value/EBITDA(ttm)

-17.15

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

44.65

Price to Book(mrq)

2.67

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-286.92%

Profit Margin(ttm)

-320.29%

Return on Equity(ttm)

-37.87%

Return on Invested Capital(ttm)

-94.20%

Return on Assets(ttm)

-25.67%

Income Statement

Revenue(ttm)

54.59M

Revenue Per Share(ttm)

1.60

Gross Profit(ttm)

54.59M

EBITDA(ttm)3

-143.08M

Net Income Available to Common(ttm)

-157.13M

Diluted EPS(ttm)

-6.70

Share Statistics

Beta (5Y Monthly)

1.14

52-Week Change

144.54%

S&P 500 52-Week Change

18.51%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

34.14M

Dividend Yield

0.00%

Float4

33.29M

% Held by Insiders

2.50%

% Held by Institutions

75.88%

Balance Sheet

Total Cash(mrq)

684.34M

Total Cash Per Share(mrq)

20.04

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

10.42%

Quick Ratio(mrq)

10.42%

Book Value Per Share(mrq)

26.46

Cash Flow

Operating Cash Flow Per Share(ytd)

-3.63

Free Cash Flow(ytd)

-120.18M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement